Granulomatosis with polyangiitis

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase II: 3 Phase IV: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

3 trials
  • Novartis Pharma AG Commercial
    IPTACOPAN
    2023-510525-15-00 9 countries 2024 n=44
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    OBINUTUZUMAB
    2022-501557-36-00 1 country 2025 n=36 Orphan
    Recruiting
  • Charite Universitaetsmedizin Berlin KöR Academic
    IMLIFIDASE
    2024-516727-13-00 1 country 2023 n=10
    Recruiting

Phase IV

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    RITUXIMAB
    2025-522049-23-00 1 country n=70
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 2 Phase II, Phase IV 1
Novartis Pharma AG Commercial 1 Phase II 0
Charite Universitaetsmedizin Berlin KöR Academic 1 Phase II 1
New trials by year
2023
1
2024
1
2025
1
← All indication landscapes